丽珠医药(01513.HK)与德国LTS就治疗精神分裂症药品订授权协议
丽珠医药(01513.HK)公布,公司今日(3日)与德国药品研发商LTS Lohmann Therapie-Systeme AG签署授权合作协议,LTS将授予公司阿塞那平透皮贴剂(用於治疗精神分裂症)某些知识产权下的独家,包含特许权使用费,可转授权的许可权。
根据本协议约定,公司将与LTS合作开发授权产品,授权产品上市後公司将拥有其在中国大陆、香港及澳门,不包括台湾地区的独家商业化权利。公司需支付授权产品在研发、申报及上市後各阶段相应的费用,逐步金及销售提成。
公司应根据研发计划和临床试验中使用的授权产品,向LTS支付其在开发期间产生的所有人工成本。根据协议,有关费用上限为320万欧元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.